Mahamaya Lifesciences IPO is a book-built issue of ₹70.44 crore. The issue is a combination of a fresh issue of 0.56 crore shares aggregating to ₹64.28 crore and an offer for sale of 0.05 crore shares aggregating to ₹6.16 crore.
The Mahamaya Lifesciences IPO opens for subscription on November 11, 2025, and closes on November 13, 2025. The allotment for the Mahamaya Lifesciences IPO is expected to be finalised on November 14, 2025. Mahamaya Lifesciences IPO will list on BSE SME with a tentative listing date fixed as November 18, 2025.
Mahamaya Lifesciences IPO price band is set at ₹108.00 to ₹114.00 per share. The lot size for an application is 1,200 shares. The public issue received bids for 20,65,200 shares against 41,17,200 shares available, resulting in an overall subscription of 0.50 times. QIBs saw a subscription of 0.65 times their quota, NIIs at 0.64 times and retail investors at 0.36 times.
How to Check Mahamaya Lifesciences IPO Allotment Status Online on the Registrar’s Website?
Mahamaya Lifesciences’s ₹70.44 crore IPO, priced at ₹108–₹114 per share, is a book-built issue comprising a fresh issue of 0.56 crore equity shares aggregating to ₹64.28 crore and an offer for sale of 0.05 crore equity shares aggregating to ₹6.16 crore. Bidding for the issue opened on November 11, 2025, and closed on November 13, 2025. The Mahamaya Lifesciences IPO allotment status is expected to be finalised on November 14, 2025. The IPO will list on the BSE SME platform with a tentative listing date set for November 18, 2025. The lot size for an application is 1,200 shares. Retail investors subscribed 0.36 times and NIIs 0.64 times (As of Nov 13, 11:19 AM).
The table below breaks down the Mahamaya Lifesciences share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
| Investor Category | Shares Offered |
| Market Maker Shares Offered | 3,09,600 (5.01%) |
| QIB Shares Offered | 29,28,000 (47.39%) |
| − Anchor Investor Shares Offered | 17,52,000 (28.36%) |
| − QIB (Ex. Anchor) Shares Offered | 11,76,000 (19.03%) |
| NII (HNI) Shares Offered | 8,82,000 (14.27%) |
| − bNII > ₹10L | 5,88,000 (9.52%) |
| − sNII < ₹10L | 2,94,000 (4.76%) |
| Retail Shares Offered | 20,59,200 (33.33%) |
| Total Shares Offered | 61,78,800 (100.00%) |
Data Source: NSE
| Category | Subscription (times) |
| Qualified Institutional Buyers | 0.65 |
| Non-Institutional Investors | 0.64 |
| Retail Individual Investors | 0.36 |
| Total shares | 0.50 |
Note: The subscription details are as of Nov 13, 2025
Incorporated in 2002, Mahamaya Lifesciences Limited is engaged in the manufacturing, registration, and export of premium crop protection products and bioproducts focused on crop and soil health management, supporting farmers in enhancing productivity.
The company specialises in producing pesticide formulations and supplying bulk products to leading Indian agrochemical firms as well as multinational corporations (MNCs).
Mahamaya Lifesciences imports scientifically developed molecules, registers them with the Central Insecticides Board, and markets them as both technical and value-added formulations to domestic manufacturers and MNCs.
The company has also expanded its global presence through product registrations in multiple countries, including the Dominican Republic, Egypt, Ethiopia, Jordan, the UAE, and Turkey, offering high-quality products along with comprehensive data support for registrations.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Nov 13, 2025, 12:28 PM IST
Nikitha Devi
Nikitha is a content creator with 7+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
